[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100329633":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":32,"responsibleParty":49,"collaborators":10,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":10,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":10,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"General Hospital of Shenyang Military Region","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"acute ischemic stroke patient",null,"acute ischemic stroke patient acute ischemic stroke patient Patient age ≥18 years .Acute ischemic stroke patient confirmed by imaging(SWI sequence) .Time of onset: within 3 months",[13],"Other: SWI sequence",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"SWI sequence","Acute ischemic stroke patient confirmed by SWI sequence",[9],[20],{"name":21,"affiliation":5,"role":22},"chen huisheng, doctor","STUDY_DIRECTOR",[24,28],{"name":21,"role":25,"phone":26,"phoneExt":10,"email":27},"CONTACT","86-24-28897511","chszh@aliyun.com",{"name":29,"role":25,"phone":30,"phoneExt":10,"email":31},"wang xinhong, doctor","15309885658","450341972@qq.com",[33],{"facility":34,"status":35,"city":36,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"General Hospital of ShenYang Military Region","RECRUITING","Shenyang","China","CN",{"type":40,"coordinates":41},"Point",[42,43],123.43278,41.79222,{"lat":43,"lon":42},[46],{"name":47,"role":25,"phone":10,"phoneExt":10,"email":48},"Cheng Xia, Ph.D","xiacheng1975@sina.com",{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Hui-Sheng Chen","Director of neurological department","100329633","the-impact-of-anti-thrombosis-on-cerebral-microbleeds-and-intracranial-hemorrhage-in-ischemic-stroke-patients-100329633",false,"NCT03571763","The Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients","The Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients: Prospective, Multi-center, Cohort Study","Inclusion Criteria:\n\n1. Patient age ≥18 years;\n2. Acute ischemic stroke patient confirmed by imaging;\n3. Time of onset: within 3 months;\n4. Baseline SWI sequence is completed before starting the secondary prevention of ischemic stroke;\n5. Baseline SWI sequence must have at least one CMB ;\n6. NIHSS≤10\n\nExclusion Criteria:\n\n1. MRI contraindication;\n2. Hemorrhagic transformation after acute Ischemic stroke;\n3. Contraindication for antiplatelet or anticoagulation therapy;\n4. Severe head trauma or intracranial hemorrhage occurred in the past six months;\n5. obvious coagulopathy;\n6. Other intracranial lesions associated with (such as tumor, cerebral vascular malformation);\n7. other unqualified patients judged by the investigator","ALL","18 Years",{"count":63,"type":64},1875,"ESTIMATED","OBSERVATIONAL","The purpose of this prospective cohort study is to investigate whether antithrombotic therapy in the secondary prevention of ischemic stroke increases the risk of the emerging CMBs and whether the change is associated with an increased risk of intracranial hemorrhage, providing an imaging evidence for individualized antithrombotic therapy in such patients.",[68],"Ischemic Stroke",[70,71],"Cerebral Hemorrhage","anti-thrombosis","2026-04-22",{"date":74,"type":75},"2026-04-27","ACTUAL",{"date":77,"type":75},"2018-08-01",{"date":79,"type":64},"2026-12-30",{"name":5,"class":6},1]